|
Delayed
Nasdaq
01:30:00 16/06/2026 am IST
|
5-day change | 1st Jan Change | ||
| 23.50 USD | +0.09% |
|
-.--% | +159.10% |
| 17/06 | Assertio Holdings Completes Merger With Zydus Lifesciences | MT |
| 17/06 | Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 | CI |
| Market Cap | 15Cr 14Cr 13Cr 11Cr 22Cr 1.47TCr 22Cr 151.89Cr 59Cr 747.38Cr 57Cr 56Cr 2.4TCr | P/E 2024 |
-3.79x | P/E 2025 | -1.91x |
|---|---|---|---|---|---|
| Enterprise Value | 13Cr 11Cr 11Cr 9.74Cr 18Cr 1.25TCr 19Cr 128.73Cr 50Cr 633.44Cr 48Cr 47Cr 2.04TCr | EV / Sales 2024 |
0.19x | EV / Sales 2025 | 0.3x |
| Free-Float |
99.05% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Assertio Holdings
| 1 day | +0.09% | ||
| 6 months | +27.65% | ||
| Current year | +159.10% |
| Current year | 9.11 | 23.5 | |
| 1 year | 8.61 | 23.5 | |
| 3 years | 7.71 | 39 | |
| 5 years | 7.71 | 120.15 | |
| 10 years | 7.71 | 1,566.6 |
| Director | Title | Age | Since |
|---|---|---|---|
Ravi Yadavar
BRD | Director/Board Member | 26 | 16/06/2026 |
Punit Patel
BRD | Director/Board Member | - | 16/06/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/05/26 | Don | Chairman | -13,332 | 0.2069% | ||
| 05/05/26 | Free | Chairman | 4,851 | 0.0753% | ||
| 05/05/26 | Free | Director | 4,851 | 0.0753% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.09% | -.--% | +76.43% | -39.04% | 15Cr | ||
| -1.61% | +1.72% | +38.30% | +106.93% | 1,06000Cr | ||
| -0.76% | -0.84% | +35.21% | +62.70% | 62TCr | ||
| +0.39% | +4.81% | +17.81% | +83.77% | 48TCr | ||
| -0.29% | -0.99% | +64.79% | +37.06% | 35TCr | ||
| -2.03% | +1.06% | +21.08% | +42.16% | 35TCr | ||
| -1.92% | -0.29% | +10.54% | +33.20% | 27TCr | ||
| -2.36% | -1.16% | -7.14% | +8.68% | 25TCr | ||
| -1.37% | +0.04% | +38.29% | +52.33% | 22TCr | ||
| +0.17% | -0.27% | +24.40% | +96.82% | 18TCr | ||
| Average | -0.95% | +0.45% | +31.97% | +48.46% | 37.88TCr | |
| Weighted average by Cap. | -1.05% | +0.74% | +30.43% | +68.82% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 12Cr 11Cr 10Cr 9.46Cr 18Cr 1.21TCr 18Cr 124.98Cr 49Cr 614.99Cr 47Cr 46Cr 1.98TCr | 12Cr 11Cr 9.89Cr 8.98Cr 17Cr 1.15TCr 17Cr 118.73Cr 46Cr 584.24Cr 45Cr 44Cr 1.88TCr |
| Net income | -2.16Cr -1.93Cr -1.8Cr -1.63Cr -3.07Cr -209.01Cr -3.1Cr -22Cr -8.44Cr -106.21Cr -8.1Cr -7.93Cr -341.58Cr | -3.04Cr -2.71Cr -2.53Cr -2.3Cr -4.33Cr -294.18Cr -4.37Cr -30Cr -12Cr -149.49Cr -11Cr -11Cr -480.76Cr |
| Net Debt | -5.98Cr -5.34Cr -4.98Cr -4.52Cr -8.51Cr -579.05Cr -8.6Cr -60Cr -23Cr -294.24Cr -22Cr -22Cr -946.3Cr | -2.32Cr -2.07Cr -1.93Cr -1.75Cr -3.3Cr -224.23Cr -3.33Cr -23Cr -9.06Cr -113.94Cr -8.69Cr -8.5Cr -366.44Cr |
Employees
53
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ASRT Stock
Select your edition
All financial news and data tailored to specific country editions
















